Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GUSTAVO F WESTIN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1942588918
CMS profile
817217
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,399.21

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,142.60 147
Long term medical supply or device loan $166.66 2
Education $89.95 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GUSTAVO F WESTIN

NPI 1942588918 · CMS profile ID 817217

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942588918?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GUSTAVO F WESTIN, NPI 1942588918, CMS profile ID 817217. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942588918?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). GUSTAVO F WESTIN, NPI 1942588918, CMS profile ID 817217. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942588918?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
GUSTAVO F WESTIN, NPI 1942588918, CMS profile ID 817217, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1942588918?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $3,399.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $12.9108/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999536201 CMS
Merck Sharp & Dohme LLC $28.3808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048282471 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.8508/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000524205 CMS
Eisai Inc. $24.5208/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023311837 CMS
GENZYME CORPORATION $24.1508/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050234343 CMS
Daiichi Sankyo Inc. $18.4308/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006462311 CMS
Daiichi Sankyo Inc. $26.1408/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006475839 CMS
Seagen Inc. $8.2308/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995810441 CMS
PFIZER INC. $16.8908/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050492917 CMS
SERVIER PHARMACEUTICALS LLC $17.5808/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055088345 CMS
Janssen Biotech, Inc. $29.9707/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366025 CMS
Amgen Inc. $14.6607/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020584917 CMS
Gilead Sciences, Inc. $14.3707/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026013041 CMS
Merck Sharp & Dohme LLC $17.2507/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048282469 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.2707/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000518401 CMS
Puma Biotechnology, Inc. $21.4407/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059055481 CMS
Janssen Biotech, Inc. $19.1607/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366013 CMS
SERVIER PHARMACEUTICALS LLC $16.9507/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055088341 CMS
Incyte Corporation $20.6406/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044601329 CMS
Amgen Inc. $15.0306/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020584919 CMS
Celgene Corporation $24.4506/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015799315 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.4506/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000508779 CMS
Regeneron Healthcare Solutions, Inc. $26.8006/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999536191 CMS
Pharmacyclics LLC, An AbbVie Company $22.6806/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297751 CMS
Seagen Inc. $22.8306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995810381 CMS
Daiichi Sankyo Inc. $23.7206/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006437631 CMS
Janssen Biotech, Inc. $24.6506/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366055 CMS
Kite Pharma, Inc. $16.8806/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025274809 CMS
Incyte Corporation $18.6906/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044601317 CMS
Janssen Biotech, Inc. $18.8006/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366085 CMS
Gilead Sciences, Inc. $21.6706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025757729 CMS
Celgene Corporation $26.4005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015799319 CMS
Pharmacyclics LLC, An AbbVie Company $27.9105/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297749 CMS
Pharmacyclics LLC, An AbbVie Company $29.5205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998297747 CMS
GlaxoSmithKline, LLC. $18.3405/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003028641 CMS
Rigel Pharmaceuticals, Inc. $19.1705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033395571 CMS
Genentech USA, Inc. $17.9405/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040372821 CMS
AstraZeneca Pharmaceuticals LP $26.4605/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016155359 CMS
Lilly USA, LLC $26.2605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031475517 CMS
Janssen Biotech, Inc. $19.2005/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366065 CMS
Eisai Inc. $24.2505/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023311835 CMS
Puma Biotechnology, Inc. $22.5905/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059046961 CMS
BeiGene USA, Inc. $23.0605/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051194453 CMS
Gilead Sciences, Inc. $18.3605/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025880185 CMS
Janssen Biotech, Inc. $18.1604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366075 CMS
Janssen Biotech, Inc. $18.0204/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366117 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.0404/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000511983 CMS
Merck Sharp & Dohme LLC $25.9404/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048723095 CMS
Daiichi Sankyo Inc. $27.0004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006351099 CMS
Novartis Pharmaceuticals Corporation $14.0504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993272055 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,105.72 119
PY2020 $1,586.79 89
PY2021 $3,620.04 156
PY2022 $5,399.43 179
PY2023 $3,399.21 150
PY2024 $2,856.15 124
PY2025 $3,622.50 164

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $86,652.91 32
PY2023 Principal investigator $172,884.33 33
PY2022 Principal investigator $69,979.32 11
PY2021 Principal investigator $57,884.30 5
PY2020 Principal investigator $14,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,983.25 12/20/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082450854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,650.00 12/02/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082446510
Principal investigator 1 Genentech, Inc. $3,500.00 11/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463552
Principal investigator 1 Genentech, Inc. $251.00 10/21/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $421.20 09/09/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,107.96 09/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 09/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,718.55 09/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436084
Principal investigator 1 Mirati Therapeutics, Inc. $5,823.90 08/23/2024 Non-covered Recipient Entity
University Cancer And Blood Center
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1124763912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,064.38 08/05/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082433262
Principal investigator 1 Genentech, Inc. $1,794.00 07/23/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,700.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,599.68 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428654
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,492.35 04/01/2024 Non-covered Recipient Entity
University Cancer And Blood Center LLC-Bldg 700
Ph. I Brigimadlin+ ezabenlimab (BI 754091/PD-1 mAb) No dispute reported 06/30/2026 1101067745
Principal investigator 1 Mirati Therapeutics, Inc. $5,823.90 03/25/2024 Non-covered Recipient Entity
University Cancer And Blood Center
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1124763914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $187.89 03/25/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082422159
Principal investigator 1 Genentech, Inc. $1,004.00 02/27/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463557
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,853.50 01/25/2024 Non-covered Recipient Entity
University Cancer And Blood Center LLC-Bldg 700
Ph. I Brigimadlin+ ezabenlimab (BI 754091/PD-1 mAb) No dispute reported 06/30/2026 1101069103